Arxcel - Pharmaceutical Benefits Research Survey Winter 2001-2002

CLICK HERE TO REVIEW ENTIRE SURVEY

EXECUTIVE OVERVIEW
Arxcel Prescription Benefits Survey

April 2003

CONCLUSIONS

Among human resources, compensation, and benefits executives within corporate America, rising prescription benefits costs are seen as being caused by

Direct to consumer advertising,
and inflation

Corporate executives believe that the most likely solutions center.

Tiered co-payment levels or higher co-payment levels
Mail order prescription service
Patient education

Over three quarters of respondents feel that a member's co-pay should be 20% or less.

Corporate leaders are evenly split on government involvement.

Those who are opposed to government involvement primarily have a negative view of the government.

Those who are in favor of government involvement, feel that the government has to do something to help with research costs, control prices and rein in pharmaceutical companies.

CLICK HERE TO REVIEW ENTIRE SURVEY

You will need ADOBE ACROBAT READER to view this file.
If you do not have ADOBE ACROBAT READER you can DOWNLOAD IT HERE for free.